ACUMEN

Acumen is leveraging decades of learnings to deliver treatments FOR the benefit of everyone impacted by this devastating disease... At Acumen, we are singularly focused on the development of targeted therapies for Alzheimer's disease, a condition that has remained untreatable for far too long... Acumen is building upon decades of research on toxic soluble amyloid beta oligomers (AβOs) to advance treatment options for Alzheimer's disease (AD). Our most advanced candidate, sabirnetug, is a monoclonal antibody that selectively targets toxic soluble AβOs for the treatment of early AD. It is designed to have disease-modifying benefits with an improved safety profile, while potentially providing symptomatic benefit for Alzheimer's patients.

Primary location: Charlottesville United States